[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
May 2, 2001

Outcomes of a Trial of HIV-1 Immunogen in Patients With HIV Infection

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;285(17):2191-2195. doi:10.1001/jama.285.17.2191

To the Editor: We would like to point out that the IRC, which sponsored the study by Dr Kahn and colleagues,1 has been accused of previous attempts to improperly influence the presentation of scientific data on its HIV-1 Immunogen.

In June 1994, authors from the company published the results of a placebo-controlled trial of this agent. The authors concluded that the vaccine "may . . . stabilize the percent of CD4 cell decline."2

First Page Preview View Large
First page PDF preview
First page PDF preview
×